S0812 Patients’ Preferences for Subcutaneous or Intravenous Administration Methods in Inflammatory Bowel Diseases

Deen, Welmoed K. van; Khalil, Carine; Almario, Christopher V.; Bonthala, Nirupama; Gale, Rebecca; Patel, Dhairya; Warui, Esther; Melmed, Gil Y.; Spiegel, Brennan

doi:10.14309/01.ajg.0000705296.17553.49

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Searching the bibliographies of seven identified SLRs 9-13 identified eight additional relevant articles, which were included in the review. In total, 49 studies, comprising 38 full papers and 11 conference abstracts, [52][53][54][55][56][57][58][59][60][61][62] were included in the review.…”

Section: Study Selectionmentioning

confidence: 99%

“…25 The remaining 31 studies compared administration routes for a range of non-immunoglobulin therapies, and described preferences for IV infusion or SC injection. [55][56][57][58][59][60][61][62] Of these, 29 studies were patient surveys, [55][56][57][58][59][60][61] of which 22 were straightforward preference questionnaires [29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][55][56][57] and seven involved conjoint analyses or discrete choice experiments. [48][49][50][58][59][60][61] The remaining studies were a non-randomized interventional study 51 and a retrospective analysis of treatment choices.…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

“…62 The most common indication in the included studies of non-immunoglobulin therapies was rheumatoid arthritis (RA; 11 studies). [29][30][31][32][33][34][35][36]46,48,58 An additional ten studies involved patients with inflammatory bowel disease (IBD, comprising Crohn's disease [CD], ulcerative colitis or a mixture of the two); 37,38,45,47,49,55,57,59,61,62 two studies were conducted among patients with systemic lupus erythematosus (SLE); 39,51 two among patients with severe asthma; 40,41 and one each among patients with multiple sclerosis (MS), 60 psoriasis 50 and axial spondyloarthritis. 56 Three studies included patients with a range of conditions (most commonly RA or IBD).…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

“…2B. [29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47]51,[55][56][57]59,61,62 Two clinical studies of patient preferences for IV infusion compared with SC injection were identified. 51,62 The first was an open-label switching study, conducted in the USA, in which patients with SLE treated with IV infusions of belimumab (n = 43) switched to SC belimumab, administered using an autoinjector.…”

Section: Preferences For IV Infusion or Sc Injection Of Non-immunoglomentioning

confidence: 99%

“…Ten studies enrolled patients with IBD. 37,38,45,47,49,55,57,59,61,62 The results of these studies were mixed, with five reporting that patients preferred SC injection, 38,45,57,59,61,62 three describing an overall preference for IV infusion 37,45,55 and two finding similar preferences for the two options. 47,49 Both of the included surveys of patients with severe asthma found strong preferences for SC injection over IV infusion, with 81.3% and 100% of patients preferring the SC administration route.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

Overton¹,

Shalet²,

Somers³

et al. 2021

PPA

View full text Add to dashboard Cite

Background: For many chronic immune system disorders, the available treatments provide several options for route of administration. The objective of this systematic literature review is to inform discussions about therapy choices for individual patients by summarizing the available evidence regarding the preferences of patients with chronic immune system disorders for intravenous (IV) or subcutaneous (SC) administration. Methods: Searches of the MEDLINE, Embase and Cochrane Library databases were conducted using terms designed to capture studies reporting patient preferences between IV and SC therapy published in English. Relevant studies were limited to those in which mode of administration, including treatment frequency and setting, was the main difference between comparators. Results: In total, 49 studies were included in the review. Among 18 studies that compared IV and SC immunoglobulin therapy, 16 found patients to prefer the SC administration route. The results of the 31 studies comparing IV infusion and SC injection of non-immunoglobulin therapies were mixed, with patients favoring SC administration in 20, IV infusion in seven, and having no overall preference in four. Patient experience had a strong effect on preferences, with treatment-experienced patients preferring their current administration route in most studies. Patients preferring SC administration tended also to prefer treatment at home, mainly due to the convenience and comfort of home treatment and the avoidance of having to attend hospital. By contrast, patients preferring IV infusion tended to cite the lower treatment frequency and a dislike of self-injecting, and preferred hospital treatment, mainly due to the presence of healthcare professionals and resulting feelings of safety. Conclusion:In general patients with chronic immune system disorders tend to be more likely to choose SC administration than IV infusion, but preferences may vary according among individuals. These findings may assist discussions around appropriate treatment choices for each patient.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Description Of the Included Studiesmentioning

confidence: 99%

Section: Description Of the Included Studiesmentioning

confidence: 99%

Section: Preferences For IV Infusion or Sc Injection Of Non-immunoglomentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

Overton¹,

Shalet²,

Somers³

et al. 2021

PPA

View full text Add to dashboard Cite

show abstract

Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients

Napolitano,

Settanni,

Parisio

et al. 2024

Indian J Gastroenterol

View full text Add to dashboard Cite

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

Ventress

Young

Rahmany

et al. 2021

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims Subcutaneous (SC) vedolizumab presents the opportunity for inflammatory bowel disease (IBD) patients to manage their treatment at home. There is currently no data on the process of transitioning patients established on intravenous (IV) to SC as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC 12 weeks following the transition. Methods 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at week 12 (W12) after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control patient-reported outcome measures (PROMs) and faecal calprotectin (FCP). Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed. Results 124 patients agreed to transition, of which 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed (31µg/g vs. 47µg/g; p=0.008), although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions (15%). Based on this cohort of patients, an expected reduction of £572,000 per annum is likely to be achieved. Conclusions Transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.

show abstract

S0812 Patients’ Preferences for Subcutaneous or Intravenous Administration Methods in Inflammatory Bowel Diseases

Cited by 3 publications

References 0 publications

Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

Contact Info

Product

Resources

About